CD69 is a classical early marker of T cell activation after stimulation of the T‐cell receptor,[27] and CD103 is an integrin marker that is markedly upregulated when T cells infiltrate the tumor, which indirectly indicates simultaneous T cell activation.[28] Compared with those in the control group and the EtOH group, the proportions of CD69+ and CD103+ T cells were both significantly elevated in the LAA group (Figure 3H), which implied that LAA could drive T cell activation in vitro. The gene discussed is CD69; the disease is neoplasm.